Screener
Rigel Pharmaceuticals RIGL Common Stock
Common Stock at other companies
Other financials
Where this comes from
Reported directly by Rigel Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:CommonStockValue.
The source filing: Rigel Pharmaceuticals’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 4:05 PM EDT
- Fiscal quarter
- Q4 FY2026
- Calendar quarter
- Q4 2026
- Accession
- 0001034842-26-000032
| Line item | As of / March 31, 2026 | As of / December 31, 2025 ⁽¹⁾ |
|---|---|---|
| Total liabilities | 104,711 | 122,114 |
| Commitments | ||
| Stockholders’ equity: | ||
| Common stock | 18 | 18 |
| Additional paid-in capital | 1,414,394 | 1,414,322 |
| Accumulated other comprehensive (loss) income | (128) | 181 |
| Accumulated deficit | (1,014,387) | (1,023,041) |
| Total stockholders’ equity | 399,897 | 391,480 |
Item 1. Financial Statements
FAQ
- What is Rigel Pharmaceuticals's common stock?
- Rigel Pharmaceuticals (RIGL) reported common stock of $18K in Q1 2026.
- How has Rigel Pharmaceuticals's common stock changed year-over-year?
- Rigel Pharmaceuticals's common stock decreased by 0.0% year-over-year, from $18K to $18K.
- What is the long-term trend for Rigel Pharmaceuticals's common stock?
- Over 5 years (2020 to 2025), Rigel Pharmaceuticals's common stock has grown at a -36.1% compound annual growth rate (CAGR), from $169K to $18K.
- What does common stock mean?
- The par value of all common shares issued and outstanding, typically a nominal amount ($0.01 or $0.001 per share).
Ask your AI about Rigel Pharmaceuticals's common stock.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude